<DOC>
	<DOCNO>NCT02351752</DOCNO>
	<brief_summary>IgA nephropathy common type primary glomerulonephritis might cause deposition immune complex contain IgA mesangium cause local immune activation . Hydroxychloroquine reduce activation dendritic cell inflammatory process show potential effect treatment patient IgA nephropathy . The investigator study recruite IgA nephropathy patient proteinuria range 0.75 3.5g/d even three-month treatment sufficient ACEi/ARB . The patient treat Hydroxychloroquine 300-400mg/d accord eGFR . The proteinuria record every two month total four month . Then , drug stop two month observation change proteinuria .</brief_summary>
	<brief_title>Hydroxychloroquine Sulfate Reduction Proteinuria Patients With IgA Nephropathy : Self- Controlled Study</brief_title>
	<detailed_description>Immunoglobulin A ( IgA ) nephropathy common type primary glomerulonephritis worldwide . Several study indicate 6-43 % IgA nephropathy patient would develop end-stage kidney disease ( ESKD ) period 10 year . The clinical risk factor progression hypertension , protienuria , impaired renal function histologic lesion presentation . There well accept optimal therapy patient IgA . Current establish therapy include full RAS inhibition optimal blood pressure control patient proteinuria and/or hypertension . Hydroxychloroquine use many year treat malaria . It also use treat systemic lupus erythematosus , rheumatic disorder like rheumatoid arthritis Sj√∂gren 's Syndrome . Recently , several study find Hydroxychloroquine could reduce risk ESRD patient lupus nephrits . The mechanism treatment n't well know far . Some investigator find Hydroxychloroquine increase lysosomal pH antigen present cell . In inflammatory condition , block toll-like receptor plasmacytoid dendritic cell ( PDCs ) . Toll-like receptor 9 ( TLR 9 ) , recognize DNA-containing immune complex , lead production interferon cause dendritic cell mature present antigen T cell . Hydroxychloroquine , decrease TLR signaling , reduce activation dendritic cell inflammatory process . The pathogenesis IgA nephropathy include deposition immune complex contain IgA mesangium cause local immune activation injury kidney . Therefore , Hydroxychloroquine might potential effect anti-inflammation patient IgA nephropathy , reduce proteinuria renal protect effect . Our study recruite IgA nephropathy patient proteinuria range 0.75 3.5g/d even three-month treatment sufficient ACEi/ARB . The patient treat Hydroxychloroquine 300-400mg/d accord eGFR . The proteinuria record every two month total four month . Then , drug stop two month observation change proteinuria .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>1. primary IgA nephopathy 2. age 1875 year 3. proteinuria range 0.75 3.5g/d even threemonth treatment sufficient ACEi/ARB 4. eGFR &gt; 30ml/min/1.73m2 1. immune suppressive agent recent one year 2. crescent glomerulonephritis , might use immune suppressive agent 3. chronic hepatic disease 4. myocardial infarction 5. malignant hypertension 6. stroke 7. malignant tumor 8. retinopathy 9. contraindication Hydroxychloroquine 10. pregnancy breastfeed woman 11. life expectancy le 6 month 12. clinical trial 13. suitable study judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>